InMed Pharmaceuticals Q2 2024 Earnings Report $4.40 +0.26 (+6.28%) (As of 12/20/2024 05:45 PM ET) Earnings History InMed Pharmaceuticals EPS ResultsActual EPS-$3.80Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInMed Pharmaceuticals Revenue ResultsActual Revenue$1.24 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInMed Pharmaceuticals Announcement DetailsQuarterQ2 2024Date2/13/2024TimeN/AConference Call ResourcesINM Earnings History Your chance to get on the next “60-Second Trade” (Ad)Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! InMed Pharmaceuticals Earnings HeadlinesInMed Pharmaceuticals Inc. Holds 2024 Annual General Meeting - Elects Directors and Appoints AuditorDecember 21 at 2:07 AM | americanbankingnews.comInMed’s Study Highlights Cannabinol’s Potential in SkincareNovember 19, 2024 | markets.businessinsider.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.December 22, 2024 | Crypto Swap Profits (Ad)InMed Pharmaceuticals: InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business UpdateNovember 15, 2024 | finanznachrichten.deInMed Pharmaceuticals Makes Progress on Alzheimer’s DrugNovember 15, 2024 | markets.businessinsider.comInMed Pharmaceuticals sets date for annual shareholder meetingSeptember 28, 2024 | investing.comSee More InMed Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like InMed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InMed Pharmaceuticals and other key companies, straight to your email. Email Address About InMed PharmaceuticalsInMed Pharmaceuticals (NASDAQ:INM), a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.View InMed Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
